Rating Change
Cantor Fitzgerald analysts initiated coverage on Milestone Pharmaceuticals Inc. (NASDAQ:MIST) with a rating of Overweight on August 20, 2026.
new coverageNASDAQ:MIST
Cantor Fitzgerald Initiates Coverage on Milestone Pharmaceuticals Inc. (MIST) with Overweight
Cantor Fitzgerald analysts initiated coverage on Milestone Pharmaceuticals Inc. (NASDAQ:MIST) with a rating of Overweight on August 20, 2026.
At publication ·
What changed
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) · new coverage
- Firm
- Cantor Fitzgerald
- Rating
- Overweight
- Price at event
- $1.07
- Market capitalization
- $252.5M
At a glance
Key takeaways
- Cantor Fitzgerald initiated coverage of Milestone Pharmaceuticals (MIST) with an Overweight rating on August 20, 2026.
- MIST trades at $1.07 with a market capitalization of $252.5 million.
Market Context
Milestone Pharmaceuticals Inc. operates in the Healthcare sector. The stock currently trades at $1.07 with a market capitalization of $252.5M.
Analyst coverage from Cantor Fitzgerald provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Milestone Pharmaceuticals Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Milestone Pharmaceuticals Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 20, 2026 | Cantor Fitzgerald | Overweight | N/A |
| May 14, 2026 | Wells Fargo | Overweight | N/A |
| Jan 06, 2026 | HC Wainwright & Co. | Buy | N/A |
| Dec 16, 2025 | Wells Fargo | Overweight | N/A |
| Dec 15, 2025 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View MIST Stock Page
Frequently Asked Questions
What does the Overweight rating mean for MIST?
A rating of Overweight from Cantor Fitzgerald reflects the analyst's outlook on Milestone Pharmaceuticals Inc. (NASDAQ:MIST). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the MIST forecast page.